Anika Therapeutics (ANIK) Change in Receivables (2010 - 2026)

Anika Therapeutics (ANIK) has reported Change in Receivables for 17 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Receivables rose 35.92% year-over-year to $3.2 million in Q2 2026; TTM through Jun 2026 was $5.7 million, a 361.27% increase from a year earlier, with the FY2025 full-year figure at -$408000.0, up 87.88% from the prior year.
• Change in Receivables was $3.2 million for Q2 2026 at Anika Therapeutics, up from $2.2 million in the prior quarter.
• Over five years, Change in Receivables peaked at $6.2 million in Q2 2023 and troughed at -$4.8 million in Q3 2024.
• A 5-year average of $476055.6 and a median of $1.3 million in 2023 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables plunged 959.27% in 2023 and jumped 196.38% in 2024, its largest moves.
• Over 5 years, Change in Receivables stood at $647000.0 in 2022, then soared by 70.63% to $1.1 million in 2023, then jumped by 196.38% to $3.3 million in 2024, then slumped by 52.78% to $1.5 million in 2025, then jumped by 108.93% to $3.2 million in 2026.
• The last three Change in Receivables figures came in at $3.2 million (Q2 2026), $2.2 million (Q1 2026), and $1.5 million (Q4 2025), per Business Quant data.